AXNX Stock Cash Flow Statements

Axonics Modulation Technologies Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Axonics Modulation Technologies Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31

cash flows from operating activities
net income	-21,000	6,899,000	-19,112,000	6,574,000	3,928,000	-7,342,000	-9,248,000	665,000	-16,252,000	-21,443,000	-22,668,000	-15,166,000	-17,250,000	-25,148,000	-22,503,000	-11,348,000	-9,168,000	-19,783,000	-14,616,000	-22,751,000	-25,006,000	-19,061,000	-13,117,000	-9,665,000
adjustments to reconcile net income to net cash from operating activities
depreciation and amortization	3,215,000	2,901,000	3,182,000	3,192,000	3,254,000	3,228,000	2,813,000	2,880,000	2,921,000	2,891,000	3,029,000	2,643,000	2,690,000	2,660,000	1,133,000	488,000	447,000	426,000	380,000	311,000	310,000	294,000	276,000	283,000
stock-based compensation	8,231,000	8,611,000	9,551,000	11,148,000	11,470,000	11,204,000	10,714,000	8,757,000	8,218,000	7,905,000	7,138,000	6,844,000	6,690,000	6,327,000	5,303,000	3,582,000	3,775,000	3,816,000	3,922,000	2,921,000	2,782,000	1,875,000	1,142,000	247,000
acquired in-process research & development
benefit from allowance of credit losses	87,000	32,000	637,000
change in fair value of contingent consideration				0	0	600,000	1,800,000	2,100,000	8,100,000
deferred income taxes	-1,752,000	7,854,000	-2,060,000
other items	121,000	2,759,000	1,136,000												-577,000	23,000	61,000
changes in operating assets and liabilities
accounts receivable	-5,353,000	-6,721,000	6,058,000	-8,267,000	-1,608,000	-7,226,000	4,670,000	-7,748,000	-960,000	-8,855,000	1,595,000	-2,329,000	-1,083,000	-4,106,000	-1,480,000	-620,000	-3,411,000	6,655,000	-13,405,000	-7,000,000	332,000	-482,000	-377,000	-208,000
inventory	-8,202,000	-14,999,000	-14,419,000	-6,427,000	-4,846,000	-4,360,000	-10,120,000	2,167,000	36,000	3,205,000	3,015,000	5,563,000	-125,000	647,000	-7,193,000	-18,753,000	-14,173,000	-10,856,000	-3,571,000	-2,956,000	-4,728,000	-2,911,000	-1,391,000	-1,648,000
prepaid expenses and other current assets	-2,603,000	802,000	2,467,000	-8,589,000	-1,805,000	-859,000	850,000	-2,698,000	322,000	40,000	1,474,000	-2,015,000	570,000	-355,000	860,000	-2,215,000	377,000	752,000	223,000	-1,843,000	200,000	-47,000	938,000	-2,098,000
other assets	-167,000	-292,000	-319,000	-307,000	-458,000	-1,734,000	-134,000	-305,000	81,000	42,000	-25,000	48,000	8,000	-181,000	-100,000	-106,000	-100,000	-112,000	228,000	28,000	-322,000	1,000	-6,000	185,000
accounts payable	675,000	3,574,000	-2,685,000	3,437,000	2,609,000	-2,625,000	5,593,000	-1,049,000	364,000	-376,000	2,529,000	-2,924,000	1,148,000	-2,000,000	914,000	1,245,000	-1,313,000	3,288,000	1,558,000	1,650,000	1,677,000	453,000	-1,334,000	1,453,000
accrued liabilities	-5,365,000	-3,692,000	4,228,000	4,510,000	345,000	-1,086,000	118,000	-708,000	158,000	682,000	900,000	-998,000	122,000	469,000	-1,569,000	685,000	1,934,000	638,000	936,000	-1,466,000	674,000	1,266,000	681,000	-83,000
accrued compensation and benefits	11,197,000	8,384,000	1,350,000	2,058,000	443,000	3,718,000	-6,663,000	3,736,000	841,000	3,460,000	-4,925,000	3,108,000	2,113,000	1,849,000	-915,000	-1,568,000	2,227,000	1,786,000	128,000
operating lease liabilities	859,000	866,000	750,000
other liabilities					0
net cash from operating activities	922,000	16,978,000	-9,236,000	5,630,000	12,344,000	-19,209,000	-781,000	9,353,000	3,847,000	-842,000	-9,167,000	-6,776,000	-2,994,000	-11,953,000	-25,583,000	-28,314,000	-19,146,000	-12,975,000	-23,307,000	-28,136,000	-23,904,000	-18,359,000	-13,055,000	-9,296,000
capex	-3,317,000	-1,238,000	-3,059,000	-1,307,000	-1,193,000	-256,000	-794,000	-335,000	-963,000	-634,000	-291,000	-1,084,000	-684,000	-370,000	-123,000	-1,023,000	-648,000	-553,000	-714,000	-377,000	-233,000	-379,000	-350,000	-222,000
free cash flows	-2,395,000	15,740,000	-12,295,000	4,323,000	11,151,000	-19,465,000	-1,575,000	9,018,000	2,884,000	-1,476,000	-9,458,000	-7,860,000	-3,678,000	-12,323,000	-25,706,000	-29,337,000	-19,794,000	-13,528,000	-24,021,000	-28,513,000	-24,137,000	-18,738,000	-13,405,000	-9,518,000
cash flows from investing activities
purchases of property and equipment	-3,317,000	-1,238,000	-3,059,000	-1,307,000	-1,193,000	-256,000	-794,000	-335,000	-963,000	-634,000	-291,000	-1,084,000	-684,000	-370,000	-123,000	-1,023,000	-648,000	-553,000	-714,000	-377,000	-233,000	-379,000	-350,000	-222,000
purchases of short-term investments	-69,103,000	-143,399,000	-27,742,000	-137,690,000	-114,298,000	-122,307,000	-52,309,000	-46,674,000	-118,438,000											-1,194,000	-1,979,000	-22,933,000	-10,298,000	-55,093,000
proceeds from sales and maturities of short-term investments	142,549,000	67,464,000	169,033,000	101,075,000	104,438,000	53,940,000	53,797,000	36,979,000								0	0	0	12,592,000	13,913,000	19,668,000	34,752,000	14,697,000
net cash from investing activities	70,129,000	-77,173,000	138,232,000	-37,922,000	-11,053,000	-68,623,000	694,000	-10,030,000	-99,401,000	-10,632,000	-291,000	-1,084,000	-684,000	-370,000	-140,864,000	-1,023,000	-648,000	-553,000	11,878,000	12,342,000	17,456,000	11,440,000	4,049,000	-48,115,000
cash flows from financing activities
payment of contingent consideration recognized at acquisition					0
proceeds from exercise of stock options	2,525,000	241,000	248,000	578,000	878,000	864,000	1,930,000	161,000	3,577,000	480,000	1,444,000	318,000	1,523,000	2,095,000	2,821,000	1,055,000	1,296,000	1,008,000	344,000	43,000	111,000	308,000	44,000	3,000
net cash from financing activities	2,525,000	241,000	248,000	578,000	878,000	-6,766,000	1,930,000	161,000	131,883,000	480,000	1,444,000	202,000	1,523,000	112,573,000	56,215,000	1,055,000	1,296,000	141,495,000	344,000	110,492,000	111,000	308,000	44,000	135,579,000
effect of exchange rate changes on cash, cash equivalents, and restricted cash	710,000	-1,269,000	1,702,000
net increase in cash, cash equivalents, and restricted cash	74,286,000	-61,223,000	130,946,000
cash, cash equivalents and restricted cash, beginning of year	0	0	117,525,000
cash, cash equivalents and restricted cash, end of period	74,286,000	-61,223,000	248,471,000
supplemental disclosure of cash flow information
cash paid for interest				14,000	16,000			0	0	0	1,000	0	1,000	2,007,000	170,000	253,000	256,000	264,000	329,000	339,000	367,000	370,000	360,000	358,000
cash paid for taxes	78,000	367,000	403,000	161,000	0			23,000	5,000			0	0							0	0			0
noncash investing and financing activities
property and equipment acquired but not yet paid		-23,000	30,000	196,000	-34,000	25,000	16,000	38,000
property and equipment acquired from tenant improvement allowance	0	784,000	4,116,000
common stock issuance for acquired in-process research & development				0
loss on disposal of property and equipment
acquired in-process research and development
amortization of debt issuance costs												0	0	4,424,000	567,000	180,000	180,000	179,000	235,000	214,000	225,000	269,000	165,000
(reversal of) benefit from allowance of credit losses
changes in operating assets and liabilities, net of business acquisition
payment of contingent consideration
acquisition of a business, net of cash acquired												0	0	0	-140,741,000
payment of debt issuance costs												0	0	0	-106,000									0
proceeds from debt												0	0	0	75,000,000									10,000,000
repayment of debt												-116,000	0	-79,500,000	-21,500,000
proceeds from offering of common stock upon follow-on public offering								0
payment of common stock offering costs upon follow-on public offering								0
effect of exchange rate changes on cash, cash equivalents and restricted cash
net increase in cash, cash equivalents and restricted cash
cash and cash equivalents, beginning of year				0	0	0	238,846,000	0	0	0	220,878,000	0	0	0	241,181,000	0	0	0	171,082,000	0	0	0	98,306,000	0
cash, cash equivalents and restricted cash, end of year
common stock issuance for business acquisition												0	0	0	55,728,000
contingent consideration for business acquisition												0	0	880,000	6,750,000
common stock issuance for exclusive license asset												0	0	0	3,637,000
accrued loan fees as debt issuance costs												0	0	0	4,500,000									750,000
benefit from (reversal of) allowance of credit losses					13,000	45,000	1,000
deferred income taxes and other items					-988,000	-516,000	-1,184,000	1,446,000	8,000	-428,000	-1,210,000	-4,379,000	2,089,000
lease liabilities
effect of exchange rate changes on cash and cash equivalents					-189,000	-164,000	-584,000	-1,969,000	1,766,000	1,050,000	316,000	-261,000	-188,000	-72,000	13,000	183,000	99,000	-108,000	-177,000	153,000	-112,000	-43,000	-10,000	-10,000
net increase in cash and cash equivalents							1,259,000	-2,485,000				-7,919,000	-2,343,000			-28,099,000	-18,399,000					-6,654,000	-8,972,000	78,158,000
cash and cash equivalents, end of period					1,980,000	-94,762,000	240,105,000		38,095,000	-9,944,000	213,180,000		-2,343,000	100,178,000	130,962,000		-18,399,000	127,859,000	159,820,000		-6,449,000	-6,654,000	89,334,000
lease liability						-333,000	9,000	18,000	17,000	16,000	20,000	28,000	34,000	39,000	42,000	52,000	142,000	155,000	161,000	-30,000	-48,000	-16,000	-32,000	-32,000
net decrease in cash and cash equivalents										-9,944,000	-7,698,000				-110,219,000				-11,262,000
common stock issuance for acquired in-process research and development
cash and cash equivalents, end of year
reversal of allowance of credit losses									-7,000	-11,000	-39,000
change in property and equipment acquired but not yet paid										246,000	267,000
benefit from doubtful accounts													0	-27,000	-65,000	0	-124,000	0	514,000
proceeds from issuance of common stock upon follow-on public offering													0			0	0
payment of common stock issuance costs upon follow-on public offering													0			0	0
forgiveness of stock subscriptions receivable
change in fair value of warrants
proceeds from issuance of common stock upon initial public offering
payment of common stock issuance costs upon initial public offering
proceeds from issuance of preferred stock and noncontrolling interest																								0
payment of preferred stock issuance costs																								0
repurchase of common stock
common stock issuance on stock option exercises for promissory notes																								0
warrants issued as debt issuance costs																								493,000
proceeds from sale of short-term investments																								7,200,000

We provide you with 20 years of cash flow statements for Axonics Modulation Technologies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Axonics Modulation Technologies stock. Explore the full financial landscape of Axonics Modulation Technologies stock with our expertly curated income statements.

The information provided in this report about Axonics Modulation Technologies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.